Adam Jess Bakker, MD | |
4010 W 65th St, Edina, MN 55435-1706 | |
(952) 456-7000 | |
(952) 456-7001 |
Full Name | Adam Jess Bakker |
---|---|
Gender | Male |
Speciality | Orthopedic Surgery |
Experience | 17 Years |
Location | 4010 W 65th St, Edina, Minnesota |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1538359757 | NPI | - | NPPES |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Infinite Health Collaborative Pa | 1052225042 | 772 |
Novacare Outpatient Rehabilitation East Inc | 3678480290 | 617 |
News Archive
Neuros Medical, Inc., a medical device company, announced promising results today from their recently completed feasibility study. The study was the first human test of the Company's patented high frequency Electrical Nerve Block™ technology and focused on patients with chronic amputation pain which affects nearly one million patients in the U.S. During the study, four of the five patients reported their pain was reduced to zero.
Bristol-Myers Squibb will soon announce an agreement that will provide additional cost savings to cash-strapped ADAPs nationwide. The agreement, with the ADAP Crisis Task Force (ACTF) of the National Alliance of State & Territorial AIDS Directors, is expected to be announced any day. BMS has been the target of a sustained advocacy campaign led by AHF over its pricing of its key AIDS drug Reyataz.
Inhibitex, Inc. today announced that the independent data safety monitoring board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with complete 30-day follow-up safety data on the third quartile (75%) of the patients that the Company plans to enroll in the trial. Based upon its review, the DSMB recommended that the trial continue to completion without modification.
In a pair of related studies, a team of Yale researchers has found a way to reverse type-2 diabetes and liver fibrosis in mice and has shown that the underlying processes are conserved in humans.
In the April 18 issue of Science, scientists from the Scuola Normale Superiore in Pisa, Italy and the Neuroscience Centre at the University of Helsinki, Finland, provide new information about the mechanism of action of antidepressant drugs.
› Verified 4 days ago
Entity Name | Infinite Health Collaborative Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1164474250 PECOS PAC ID: 1052225042 Enrollment ID: O20040209000574 |
News Archive
Neuros Medical, Inc., a medical device company, announced promising results today from their recently completed feasibility study. The study was the first human test of the Company's patented high frequency Electrical Nerve Block™ technology and focused on patients with chronic amputation pain which affects nearly one million patients in the U.S. During the study, four of the five patients reported their pain was reduced to zero.
Bristol-Myers Squibb will soon announce an agreement that will provide additional cost savings to cash-strapped ADAPs nationwide. The agreement, with the ADAP Crisis Task Force (ACTF) of the National Alliance of State & Territorial AIDS Directors, is expected to be announced any day. BMS has been the target of a sustained advocacy campaign led by AHF over its pricing of its key AIDS drug Reyataz.
Inhibitex, Inc. today announced that the independent data safety monitoring board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with complete 30-day follow-up safety data on the third quartile (75%) of the patients that the Company plans to enroll in the trial. Based upon its review, the DSMB recommended that the trial continue to completion without modification.
In a pair of related studies, a team of Yale researchers has found a way to reverse type-2 diabetes and liver fibrosis in mice and has shown that the underlying processes are conserved in humans.
In the April 18 issue of Science, scientists from the Scuola Normale Superiore in Pisa, Italy and the Neuroscience Centre at the University of Helsinki, Finland, provide new information about the mechanism of action of antidepressant drugs.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Adam Jess Bakker, MD 4200 Dahlberg Dr, Suite 300, Golden Valley, MN 55422-4840 Ph: (952) 512-5600 | Adam Jess Bakker, MD 4010 W 65th St, Edina, MN 55435-1706 Ph: (952) 456-7000 |
News Archive
Neuros Medical, Inc., a medical device company, announced promising results today from their recently completed feasibility study. The study was the first human test of the Company's patented high frequency Electrical Nerve Block™ technology and focused on patients with chronic amputation pain which affects nearly one million patients in the U.S. During the study, four of the five patients reported their pain was reduced to zero.
Bristol-Myers Squibb will soon announce an agreement that will provide additional cost savings to cash-strapped ADAPs nationwide. The agreement, with the ADAP Crisis Task Force (ACTF) of the National Alliance of State & Territorial AIDS Directors, is expected to be announced any day. BMS has been the target of a sustained advocacy campaign led by AHF over its pricing of its key AIDS drug Reyataz.
Inhibitex, Inc. today announced that the independent data safety monitoring board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with complete 30-day follow-up safety data on the third quartile (75%) of the patients that the Company plans to enroll in the trial. Based upon its review, the DSMB recommended that the trial continue to completion without modification.
In a pair of related studies, a team of Yale researchers has found a way to reverse type-2 diabetes and liver fibrosis in mice and has shown that the underlying processes are conserved in humans.
In the April 18 issue of Science, scientists from the Scuola Normale Superiore in Pisa, Italy and the Neuroscience Centre at the University of Helsinki, Finland, provide new information about the mechanism of action of antidepressant drugs.
› Verified 4 days ago
Stefano M Sinicropi, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7373 France Ave S Ste 408, Edina, MN 55435 Phone: 651-430-3800 Fax: 651-430-1447 | |
Gregory John Folsom, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8100 W 78th St, Edina, MN 55439 Phone: 952-946-9777 | |
Dr. Brian Peter Bjerke, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4010 W 65th St, Edina, MN 55435 Phone: 952-456-7000 Fax: 952-456-7001 | |
Douglas Albert Drake, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 4010 W 65th St, Edina, MN 55435 Phone: 952-456-7000 Fax: 952-456-7001 | |
Rodney Holmes Peterson, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3250 W 66th St, Suite 100, Edina, MN 55435 Phone: 952-920-0970 Fax: 952-922-1605 | |
Kayvon Scott Riggi, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4010 W 65th St, Edina, MN 55435 Phone: 952-456-7000 Fax: 952-456-7001 | |
Dr. Maryclare Kearns Mccarthy, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4010 W 65th St, Edina, MN 55435 Phone: 952-835-0750 Fax: 952-835-0662 |